APA

Kuwatsuka Y., Minami M., Minami Y., Sugimoto K., Hayakawa F., Miyata Y., Abe A., Goff D. J., Kiyoi H. & Naoe T. (20121002). The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells. : Blood cancer journal.

Chicago

Kuwatsuka Y, Minami M, Minami Y, Sugimoto K, Hayakawa F, Miyata Y, Abe A, Goff D J, Kiyoi H and Naoe T. 20121002. The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells. : Blood cancer journal.

Harvard

Kuwatsuka Y., Minami M., Minami Y., Sugimoto K., Hayakawa F., Miyata Y., Abe A., Goff D. J., Kiyoi H. and Naoe T. (20121002). The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells. : Blood cancer journal.

MLA

Kuwatsuka Y, Minami M, Minami Y, Sugimoto K, Hayakawa F, Miyata Y, Abe A, Goff D J, Kiyoi H and Naoe T. The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells. : Blood cancer journal. 20121002.